45 results about "Shigella sonnei" patented technology

The invention discloses a fourteen-food-borne pathogenic bacterium multiplex PCR detection primer set and a kit. The detection primer set is composed of primer pairs for detecting salmonella, Shigella, Vibrio parahemolyticus, campylobacter jejuni, campylobacter coli, staphylococcus aureus, bacillus cereus, Listeria monocytogenes, yersinia enterocolitica, enterobacter sakazakii, Escherichia coli, vibrio cholerae, Escherichia coli O157, aeromonas hydrophila and internal positive control. A multiplex PCR detection method based on an ordinary PCR platform is built, multiplex PCR reactions are carried out on genomic DNA, extracted from a sample to be tested, of bacteria in the same reaction system through the primer pairs acquired through analysis and design, and whether the food-borne pathogenic bacteria are contained in the sample or not is judged through the electrophoretic analysis of reaction products.

The invention discloses preparation and application of Clostridium butyricum and a live Clostridium butyricum preparation; Clostridium butyricum LXKJ-1 is collected in China Center for Type Culture Collection on 24 March, 2016 under CCTCC NO: M201613. A seed medium, fermentation medium formulation, culture conditions for Clostridium butyricum and a production of a preparation of live Clostridium butyricum are also disclosed. The Clostridium butyricum provided herein is tolerant to acids, bases and high temperature, is highly capable of producing butyric acid, can inhibit animal pathogens, such as Escherichia coli, Salmonella, Shigella, Staphylococcus aureus, Listeria monocytogenes, and Clostridium perfringens, and can prevent diarrhea in livestock and poultry due to Escherichia coli, Salmonella and Clostridium perfringens, improving intestinal flora balance, promoting the growth of livestock and poultry, relieving constipation in sows, improving egg weight for layers, improving eggshell quality for layers, and decreasing egg-feed ratio.

The strain of micro-organism Lactobacillus fermentum ME-3 is a novel anti-microbial and anti-oxidative probiotic. It has a high anti-microbial effect on Escherichia coli, Shigella sonnei, Staphylococcus aureus, Salmonella typhimurium, and moderate activity against Helicobacter pylori strains. The strain of micro-organism possesses Mn-superoxide dismutase and both its lysates and intact cells have high anti-oxidative activity, increasing the glutathione red-ox ratio in blood sera and able to capture toxic hydroxyl radicals. The strain of micro-organism could be used as a probiotic for the production of functional food (yoghurt, cheese) and non-comestibles (tablets, capsules) for the prophylaxis of intestinal and uroinfections, both for the prevention and treatment of chronic diseases, caused by prolonged oxidative stress.

The present invention relates to a bacteriophage PA1Φ belonging to family Siphoviridae, characterized that it is capable of killing one or more bacteria strains selected from a group comprising Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus homonis, Shigella sonnei, Listeria monocytogenes and Streptococcus pneumonia, and contains a full-length genome of SEQ ID NO: 1.

According to the present invention, the bacteriophage PA1Φ can be used to kill said bacteria and reduce the same effectively. Also, it can be used to remove biofilms generated by said bacteria. Especially, this bacteriophage is applicable for medical industry, food industry, biotechnology and the like, because it is a sort of virus that kills host bacteria without any adverse effect on human, animals and so on. In addition, this bacteriophage can kill noxious bacteria on target sites or target supports without any problem related with resistance development of bacteria.

The invention discloses a novel application of an embelin or embelin compound in bacterium inhibition. According to the novel application, the embelin or embelin compound has an effect of inhibiting enzyme activity of beta-lactamase, especially a prominent effect of inhibiting the wide anti-biological hydrolytic activity of New Delhi metallo-beta-lactamase-1, can be used for remarkably improving the sensitivity of drug-resistance bacteria on antibiotics, remarkably reducing the minimal inhibitory concentration of multiple antibiotics on superbug, reversing the drug resistance of drug-resistance bacteria and reducing clinical hazard of serious drug-resistance bacteria, and has certain bacteriostatic activity. A high-concentration embelin or embelin compound has remarkable bacteriostatic activity on staphylococcus aureus, pseudomonas aeruginosa, salmonella typhimurium, shigella sonnei, shigella flexneri, klebsiella pneumoniae, escherichia coli and other pathogenic bacteria, and even can be used for completely inhibiting bacterium growth.

The invention discloses a small rhzomorph MccY and a preparation method and application thereof. The amino acid sequence of the small rhzomorph MccY is GGRGHIAEYFSGPITQVSFYG. Compared with MccJ25 which only has bactericidal activity on a small part of serotype salmonella such as enteritis and the like, the small rhzomorph MccY has a bacteriostatic/bactericidal effect on salmonella pullorum, salmonella typhimurium, salmonella kafenkii, salmonella infantis, salmonella London and shigella sonnei, and can kill other salmonella serotypes which cannot be killed by MccJ25; the small rhzomorph MccY has a remarkable bactericidal effect on salmonella typhimurium and salmonella pullorum which are common in livestock and poultry production, also has a bacteriostatic/bactericidal effect on shigella sonnei, overcomes the defect of narrow spectrum of small rhzomorph, has breakthrough significance, and has the potential of being used as an antibiotic substitute.

The invention discloses a Shigella multivalent conjugate vaccine which includes five serotypes, i.e., Shigella dysenteriae I type, Shigella flexneri 2a type, Shigella flexneri 3a type, Shigella flexneri 6 type and Shigella sonnei; the Shigella multivalent conjugate vaccine is prepared by the steps of preparing conjugate stock solutions from specific polysaccharides of the bacteria and carrier protein, and mixing five conjugate stock solutions in a proper proportion. The prepared conjugate vaccine disclosed by the invention is applicable to immunoprophylaxis of Shigella infection.

The present inventions relates to primers for identifying Shigella flexneri serotypes comprising the sequences of SEQ ID Nos. 1 and 2, SEQ ID Nos. 3 and 4, SEQ ID Nos. 5 and 6, SEQ ID Nos. 7 and 8, SEQ ID Nos. 9 and 10, SEQ ID Nos. 11 and 12, SEQ ID Nos. 13 and 14, SEQ ID Nos. 15 and 16. These primers are specific and have a common annealing temperature. The present invention further relates to a multiplex amplification-based identification method using the primers. The present invention further relates to the use of the primers for identifying Shigella flexneri serotypes for the preparation of identification agents. The present invention further relates to a kit for identifying Shigella flexneri comprising the above primers.

The invention discloses a passion fruit fermented juice and a preparation method thereof. The passion fruit fermented juice is prepared from, by mass, 20% of passion fruit pulp, 20% of honey and 60% of purified water, wherein the raw materials are mixed, sterilized at 115 DEG C for 20 minutes, cooled to the room temperature, inoculated with 1wt% of a lactobacillus plantarum BXM2 mother solution, and subjected to standing at 37 DEG C for 20 hours to obtain the passion fruit fermented juice. The prepared passion fruit fermented juice contains the lactobacillus plantarum with the viable count of 2.35*10<7>cfu/mL, has an antibacterial effect significantly higher than a lactobacillus plantarum BXM2 fermentation broth on staphylococcus aureus, escherichia coli, Shigella sonnei, salmonella typhimurium, Listeria monocytogenes and proteus mirabilis, and increases the additional value of the passion fruit pulp, the contained lactobacillus plantarum BXM2 has beneficial effects on the human body, and the fermentation broth can improve the ability of the body to resist harmful bacteria, and has a good protective effect on human health.

The invention provides a new primer composition for detecting the presence of Shigella sonnei and a method of using the same. The primer composition and method have high specificity and sensitivity on the detection of Shigella sonnei. The invention also provides a method for extracting the nucleic acids of microorganisms in a solution sample.

The invention provides a new primer composition for detecting the presence of Shigella sonnei and a method of using the same. The primer composition and method have high specificity and sensitivity on the detection of Shigella sonnei.

The invention relates to a detection application kit for Shigella sonnei wzy and wbgV gene special nucleotides. The nucleotides comprise nucleotides shown as SEQ ID NO:1 and/or nucleotides shown as SEQ ID NO:2; nucleotides shown as SEQ ID NO:3 and/or nucleotides shown as SEQ ID NO:4. The nucleotides can be used for preparing the PCR kit for detecting Shigella sonnei. The practicability for the Shigella sonnei wzy and wbgV gene special nucleotides and the PCR kit containing the nucleotides is high. The PCR kit has the characteristics of simple and convenient preparation method, short detectionperiod, high speed, high operability, high accuracy and high sensitivity, and is easy for commercial production; however, the detection cost is relatively low.

The invention relates to a suspension chip for Shigella sonnei detection, and a detection method thereof. The suspension chip comprises a microsphere carrier and an oligonucleotide probe fixed on the carrier, wherein the oligonucleotide probe is a section of DNA sequence in Shigella sonneispecific gene rfc screened from Shigella O-antigen gene cluster. The method comprises the steps of utilizing a designed primer to amplify and mark genomic DNA of a sample to be detected, utilizing the suspension chip to perform hybridization and judging whether the sample to be detected contains the Shigella sonnei according to hybridization fluorescence intensity. The suspension chip is high in detection sensitivity, can reach the level of fg-grade genomic DNA, can meet the detection requirement of clinical samples and environmental samples, has the characteristics of high specificity, simple operation, low cost and the like, and is easy to popularize. In addition, the detection method adopts a UNG-Taq enzyme PCR reaction system, thereby greatly reducing false positive results of PCR.

A live attenuated Shigella vaccine, which is based on a rough Shigella strain lacking LPS O-antigen which is non-invasive through a mutation of the invasion plasmid, specifically for use in the immunoprophylaxis of a subject to prevent infectious diseases, preferably enteral disease, and a Shigella strain, which is a S. flexneri 2a strain with a deletion of the rfb F, ipa B and/or ipa C genes, as well as a recombinant plasmid vector based on a mutated Shigella invasion plasmid comprising a nucleotide sequence encoding at least one heterologous antigen, wherein the plasmid is mutated in at least one of the ipa B and/or ipa C genes.

For the first time, an O-specific polysaccharide antigen that is a Shigella Sonnei, phase I, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic natural compound in the form of a bacterial capsular polysaccharide. The exopolysaccharide contains a non-toxic lipid component, namely non-hydroxylated fatty acids, and exhibits low pyrogenicity and high immunogenicity. Effective, highly specific and safe vaccines for the prophylaxis and/or treatment of Shigella sonnei shigellosis are developed on the basis of the above-mentioned exopolysaccharide, as well as pharmaceutical compositions with a broad spectrum of action, in particular, in modulating immune response.

The invention discloses a wbgZ-gene-based real-time fluorescent PCR (polymerase chain reaction) method and kit for identifying Shigella sonnei. The invention firstly discloses a real-time fluorescent PCR primer pair and probe for identifying Shigella sonnei, wherein the primer pair is composed of a forward primer of which the nucleotide sequence is disclosed as SEQ ID No.1 and a reverse primer of which the nucleotide sequence is disclosed as SEQ ID No.2; and the nucleotide sequence of the probe is disclosed as SEQ ID No.3. The invention also discloses a real-time fluorescent PCR method for identifying Shigella sonnei, which comprises the following steps: extracting DNA of the sample to be detected as a template, establishing a PCR reaction system by using the primer pair and probe, and carrying out PCR amplification; and if an S-shaped amplification curve appears in the result, determining that the sample to be detected contains Shigella sonnei. The real-time fluorescent PCR method has the advantages of high sensitivity and time saving, is convenient and quick, and can be used for detecting Shigella sonnei in samples.

The present invention relates to gliocladin and its application, and belongs to the field of medical antibiotic technology. The gliocladin is obtained with the production strain and through conventional liquid or solid fermentation and extraction of the metabolite. The production strain is Gliocladium roseum Gr87 with preservation number of CGMCC No. 0807. The gliocladin has molecular expression of C21H16O2, and molecular weight 384. The gliocladin is used in preparing antibiotic for Shigella sonnei, tubercle mycobacillus, bacillus pyocyaneus, Shigella shigae, etc.

The invention discloses an MccY recombinant integrated engineering bacterium as well as a construction method and application thereof. The construction method of the MccY recombinant integrated engineering bacterium comprises the following steps: (1) connecting an sgRNA fragment (SEQ ID NO.2) with a T vector to obtain a pHsgRNA plasmid; (2) transforming the pCas9 plasmid into escherichia coli, and preparing competent cells; and then transferring the optimized repair fragment (SEQ ID NO.1) of the MccY and the pH sgRNA plasmid into competent cells, identifying, culturing, and carrying out continuous passage screening to eliminate a strain of double plasmids, so as to obtain the MccY recombinant integrated engineering bacterium. The constructed MccY recombinant integrated engineering bacterium does not have plasmids and resistance genes, does not need an inducer, can continuously and efficiently secrete and express MccY, and has an obvious inhibition effect on salmonella typhimurium, escherichia coli, shigella sonnei, shigella dysenteriae and the like.